Renaissance BioScience Overview
- Founded
- 2013
- Status
- Private
- Employees
- 18
- Latest Deal Type
- Grant
- Latest Deal Amount
- $1M
- Investors
- 4
Renaissance BioScience General Information
Description
Developer of a yeast-based RNAi production and oral delivery technology designed for gene silencing in the gastrointestinal tract. The company's technology targets the reduction of inflammation for Crohn's disease, Ulcerative colitis, or other gastrointestinal diseases and can also be used for animal health and environmentally friendly biopesticides that include yeast strains that prevent the formation of naturally occurring contaminants, enabling food industries to deliver things that need to supply, sustain and strengthen humanity.
Contact Information
Website
www.renaissancebioscience.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- 410-2389 Health Sciences Mall
- Vancouver, British Columbia V6T 1Z3
- Canada
+1 (604) 000-0000
Renaissance BioScience Timeline
Renaissance BioScience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 01-Jan-2021 | $1M | 000.00 | Completed | Generating Revenue | |
| 5. Grant | 01-Jan-2020 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 4. Accelerator/Incubator | 01-Oct-2019 | 000 | 000.00 | Completed | Generating Revenue | |
| 3. Seed Round | 00.00 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 2. Grant | 08-Jun-2017 | $370K | Completed | Generating Revenue | ||
| 1. Grant | 01-Mar-2016 | $50K | Completed | Startup |
Renaissance BioScience Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a yeast-based RNAi production and oral delivery technology designed for gene silencing in the gastrointesti
Biotechnology
Vancouver, Canada
18
As of 2022
000.00
0000000000
000.00
000 0000
m veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis au
000000000 000000000
Boulder, CO
00
As of 0000
000.00
0000
0000-00-00
00000000000
000.00
00000000
oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000000000000
Pasadena, CA
000
As of 0000
00.000
000000 - 000
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialRenaissance BioScience Competitors (4)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DMC Biotechnologies | Venture Capital-Backed | Boulder, CO | 00 | 000.00 | 00000000000 | 000.00 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
| 0000000 0000000000 | Formerly VC-backed | London, United Kingdom | 00 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
Renaissance BioScience Patents
Renaissance BioScience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019264879-A1 | Yeast for producing and delivering rna bioactive molecules and methods and uses thereof | Pending | 09-May-2018 | 000000000 | |
| CA-3099445-A1 | Yeast for producing and delivering rna bioactive molecules and methods and uses thereof | Pending | 09-May-2018 | 000000000 | |
| US-20210054379-A1 | Yeast for producing and delivering rna bioactive molecules and methods and uses thereof | Pending | 09-May-2018 | 000000000 | |
| EP-3790955-A1 | Yeast for producing and delivering rna bioactive molecules and methods and uses thereof | Pending | 09-May-2018 | 000000000 | |
| AU-2016289705-A1 | Development of an asparagine-reducing yeast by adaptive evolution and uses thereof to reduce acrylamide formation | Pending | 07-Jul-2015 | A23L5/28 |
Renaissance BioScience Executive Team (11)
Renaissance BioScience Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| John Husnik Ph.D | Renaissance BioScience | Co-Founder, Chief Executive Officer, CSO & Board Member | 000 0000 |
| Maurice Boucher | Renaissance BioScience | Co-Founder & Executive Chairman | 000 0000 |
| Morris Chen | Renaissance BioScience | Board Member | 000 0000 |
| Peter Lutwyche Ph.D | Self | Board Member | 000 0000 |
| Vick Dusik | Renaissance BioScience | Board Member | 000 0000 |
Renaissance BioScience Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialRenaissance BioScience Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Radicle | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| National Research Council Canada | Government | 000 0000 | 000000 0 | ||
| Carpere Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| NorthView Lifesciences | Venture Capital | Minority | 000 0000 | 000000 0 |